Hematoporphyrin-Derived Soluble Porphyrin−Platinum Conjugates with Combined Cytotoxic and Phototoxic Antitumor Activity
- 17 April 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (10), 2064-2078
- https://doi.org/10.1021/jm0110688
Abstract
To combine the cytotoxic activity of cisplatin and the phototoxicicity of hematoporphyrin derivatives in the same molecule, hematoporphyrin was derivatized at the two secondary alcohol positions by etherification with oligo- and poly(ethylene glycol) units. The two carboxylic acid groups of the propionate side chains were used to bind platinum fragments. The antiproliferative activity of 35 platinum complexes (0.5, 1, and 5 μM) differing in solubility and type of the platinum fragment and the corresponding porphyrin ligands were studied in tests with TCC-SUP and J82 transitional bladder cancer cells in the dark and after irradiation (λ = 600−730 nm, 24 J/cm2). The most active compounds were found among the porphyrin−platinum conjugates bearing the diammine and (RR/SS)-trans-1,2-diaminocyclohexane ligand. These porphyrin−platinum conjugates, especially the water-soluble species, such as diammine{7,12-bis[1-(poly(ethylene glycol)-750-monomethyl ether-1-yl)ethyl]-3,8,13,17-tetramethylporphyrin-2,18-dipropionato}platinum(II), are promising candidates for the development of a novel type of photosensitizers with intrinsic cytotoxicity, which due to the porphyrin constituent may selectively enrich in tumor tissues.Keywords
This publication has 39 references indexed in Scilit:
- Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancerEuropean Journal of Cancer, 2000
- Urine cytology, tumour markers and bladder cancerBritish Journal of Urology, 1998
- Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990European Journal of Cancer, 1997
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1992
- M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder: The french federation of cancer centers experienceEuropean Journal of Cancer and Clinical Oncology, 1991
- Usefulness and Limitations of Methotrexate, Vinblastine, Doxorubicin And Cisplatin for the Treatment of Advanced Urothelial CancerJournal of Urology, 1990
- A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.Journal of Clinical Oncology, 1990
- Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concernUrology, 1989
- Risk of bladder cancer by source and type of tobacco exposure: A case‐control studyInternational Journal of Cancer, 1989
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Chemotherapy for Transitional Cell Carcinoma: The Princess Margaret Hospital ExperienceJournal of Urology, 1989